{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
atogepant
to a specific field?
There is one exact (name or code) match for atogepant
Status:
US Approved Rx
(2021)
Source:
NDA215206
(2021)
Source URL:
First approved in 2021
Source:
NDA215206
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-8031 (also known as Atogepant) is piperidinonylcarboxamideazaindane derivative patented by Merck Sharp & Dohme Corp as CGRP receptor antagonist useful for prevention and treatment of Migraine. A press release in June 2018 announced positive results for MK-8031, in a Phase 2 trial of daily use for episodic migraine prevention. MK-8031appeared to show good efficacy in migraine prevention and no significant liver toxicity signal at any dose despite daily dosing for 3 months. Phase III clinical trial was initiated in 2019 and currently in progress.
Showing 1 - 4 of 4 results
Status:
US Approved Rx
(2021)
Source:
NDA215206
(2021)
Source URL:
First approved in 2021
Source:
NDA215206
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-8031 (also known as Atogepant) is piperidinonylcarboxamideazaindane derivative patented by Merck Sharp & Dohme Corp as CGRP receptor antagonist useful for prevention and treatment of Migraine. A press release in June 2018 announced positive results for MK-8031, in a Phase 2 trial of daily use for episodic migraine prevention. MK-8031appeared to show good efficacy in migraine prevention and no significant liver toxicity signal at any dose despite daily dosing for 3 months. Phase III clinical trial was initiated in 2019 and currently in progress.
Status:
Possibly Marketed Outside US
Source:
NCT04592952: Phase 4 Interventional Recruiting Migraine
(2020)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
NDA215206
(2021)
Source URL:
First approved in 2021
Source:
NDA215206
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-8031 (also known as Atogepant) is piperidinonylcarboxamideazaindane derivative patented by Merck Sharp & Dohme Corp as CGRP receptor antagonist useful for prevention and treatment of Migraine. A press release in June 2018 announced positive results for MK-8031, in a Phase 2 trial of daily use for episodic migraine prevention. MK-8031appeared to show good efficacy in migraine prevention and no significant liver toxicity signal at any dose despite daily dosing for 3 months. Phase III clinical trial was initiated in 2019 and currently in progress.
